Hassan N Ibrahim1, Dina N Murad2, Sean A Hebert2, Horacio E Adrogue2, Hana Nguyen2, Duc T Nguyen3, Arthur J Matas4, Edward A Graviss3,5. 1. Department of Medicine, Houston Methodist Hospital, Houston, Texas hnibrahim@houstonmethodist.org. 2. Department of Medicine, Houston Methodist Hospital, Houston, Texas. 3. Department of Pathology and Genomic Medicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, Texas. 4. Department of Surgery, University of Minnesota, Minneapolis, Minnesota. 5. Department of Surgery, Houston Methodist Hospital, Houston, Texas.
Abstract
BACKGROUND: Obesity is associated with the two archetypal kidney disease risk factors: hypertension and diabetes. Concerns that the effects of diabetes and hypertension in obese kidney donors might be magnified in their remaining kidney have led to the exclusion of many obese candidates from kidney donation. METHODS: We compared mortality, diabetes, hypertension, proteinuria, reduced eGFR and its trajectory, and the development of kidney failure in 8583 kidney donors, according to body mass index (BMI). The study included 6822 individuals with a BMI of <30 kg/m2, 1338 with a BMI of 30-34.9 kg/m2, and 423 with a BMI of ≥35 kg/m2. We used Cox regression models, adjusting for baseline covariates only, and models adjusting for postdonation diabetes, hypertension, and kidney failure as time-varying covariates. RESULTS: Obese donors were more likely than nonobese donors to develop diabetes, hypertension, and proteinuria. The increase in eGFR in obese versus nonobese donors was significantly higher in the first 10 years (3.5 ml/min per 1.73m2 per year versus 2.4 ml/min per 1.73m2 per year; P<0.001), but comparable thereafter. At a mean±SD follow-up of 19.3±10.3 years after donation, 31 (0.5%) nonobese and 12 (0.7%) obese donors developed ESKD. Of the 12 patients with ESKD in obese donors, 10 occurred in 1445 White donors who were related to the recipient (0.9%). Risk of death in obese donors was not significantly increased compared with nonobese donors. CONCLUSIONS: Obesity in kidney donors, as in nondonors, is associated with increased risk of developing diabetes and hypertension. The absolute risk of ESKD is small and the risk of death is comparable to that of nonobese donors.
BACKGROUND: Obesity is associated with the two archetypal kidney disease risk factors: hypertension and diabetes. Concerns that the effects of diabetes and hypertension in obese kidney donors might be magnified in their remaining kidney have led to the exclusion of many obese candidates from kidney donation. METHODS: We compared mortality, diabetes, hypertension, proteinuria, reduced eGFR and its trajectory, and the development of kidney failure in 8583 kidney donors, according to body mass index (BMI). The study included 6822 individuals with a BMI of <30 kg/m2, 1338 with a BMI of 30-34.9 kg/m2, and 423 with a BMI of ≥35 kg/m2. We used Cox regression models, adjusting for baseline covariates only, and models adjusting for postdonation diabetes, hypertension, and kidney failure as time-varying covariates. RESULTS: Obese donors were more likely than nonobese donors to develop diabetes, hypertension, and proteinuria. The increase in eGFR in obese versus nonobese donors was significantly higher in the first 10 years (3.5 ml/min per 1.73m2 per year versus 2.4 ml/min per 1.73m2 per year; P<0.001), but comparable thereafter. At a mean±SD follow-up of 19.3±10.3 years after donation, 31 (0.5%) nonobese and 12 (0.7%) obese donors developed ESKD. Of the 12 patients with ESKD in obese donors, 10 occurred in 1445 White donors who were related to the recipient (0.9%). Risk of death in obese donors was not significantly increased compared with nonobese donors. CONCLUSIONS: Obesity in kidney donors, as in nondonors, is associated with increased risk of developing diabetes and hypertension. The absolute risk of ESKD is small and the risk of death is comparable to that of nonobese donors.
Authors: Fawaz Al Ammary; Xun Luo; Abimereki D Muzaale; Allan B Massie; Deidra C Crews; Madeleine M Waldram; Mohamud A Qadi; Jacqueline Garonzik-Wang; Macey L Henderson; Daniel C Brennan; Alexander C Wiseman; Richard C Lindrooth; Jon J Snyder; Josef Coresh; Dorry L Segev Journal: Clin J Am Soc Nephrol Date: 2019-06-25 Impact factor: 8.237
Authors: Jayme E Locke; Rhiannon D Reed; Allan Massie; Paul A MacLennan; Deirdre Sawinski; Vineeta Kumar; Shikha Mehta; Roslyn B Mannon; Robert Gaston; Cora E Lewis; Dorry L Segev Journal: Kidney Int Date: 2016-12-29 Impact factor: 10.612
Authors: Julie K Heimbach; Sandra J Taler; Mikel Prieto; Fernando G Cosio; Stephen C Textor; Yogish C Kudva; George K Chow; Michael B Ishitani; Timothy S Larson; Mark D Stegall Journal: Am J Transplant Date: 2005-05 Impact factor: 8.086
Authors: Colin R Lenihan; Stephan Busque; Geraldine Derby; Kristina Blouch; Bryan D Myers; Jane C Tan Journal: J Clin Invest Date: 2015-02-17 Impact factor: 14.808
Authors: Lynn L Moore; Agostino J Visioni; M Mustafa Qureshi; M Loring Bradlee; R Curtis Ellison; Ralph D'Agostino Journal: Arch Intern Med Date: 2005-06-13
Authors: Otto A Sanchez; Laine K Ferrara; Sarah Rein; Danielle Berglund; Arthur J Matas; Hassan N Ibrahim Journal: Am J Transplant Date: 2018-04-06 Impact factor: 8.086
Authors: Naim Issa; Otto A Sánchez; Aleksandra Kukla; Samy M Riad; Danielle M Berglund; Hassan N Ibrahim; Arthur J Matas Journal: Clin Transplant Date: 2018-08-18 Impact factor: 2.863
Authors: Peter P Reese; Harold I Feldman; David A Asch; Arwin Thomasson; Justine Shults; Roy D Bloom Journal: Transplantation Date: 2009-09-15 Impact factor: 4.939